Jay Tarnow
Child & Adolescent Psychiatry · Houston, TXNPI 1619089885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,238 and has fallen 56.3% since, to $541 in 2025. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$952
- Supernus Pharmaceuticals, Inc.$796
- Takeda Pharmaceuticals U.S.A., Inc.$733
- Ironshore Pharmaceuticals Inc.$727
- AbbVie$539
- Lundbeck LLC$352
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$5008%
- Food & beverage$5,40791%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 46 | $952 |
| Supernus Pharmaceuticals, Inc. | 12 | $796 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $733 |
| Ironshore Pharmaceuticals Inc. | 36 | $727 |
| AbbVie | 31 | $539 |
| Lundbeck LLC | 19 | $352 |
| Otsuka America Pharmaceutical, Inc. | 14 | $285 |
| Sunovion Pharmaceuticals Inc. | 11 | $241 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $219 |
| Tris Pharma Inc | 12 | $198 |
| Teva Pharmaceuticals USA, Inc. | 9 | $143 |
| Neos Therapeutics, LP | 8 | $130 |
| Shire North American Group Inc | 7 | $128 |
| Noven Therapeutics, LLC | 6 | $123 |
| Johnson & Johnson | 4 | $70 |
| OWP Pharmaceuticals, Inc. | 4 | $66 |
| Adlon Therapeutics L.p. | 3 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Bausch Health US, LLC | 2 | $35 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
How this compares
$5,954 in reported general payments places this provider in the 90th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 40 | $1,859 |
| Methylphenidate ErMethylphenidate Hcl | 17 | $1,749 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 30 | $1,513 |
| Bupropion XlBupropion Hcl | 34 | $1,284 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 30 | $1,221 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,163 |
| Fluoxetine Hcl | 36 | $1,071 |
| Vilazodone Hcl | 11 | $1,058 |
| Trazodone Hcl | 76 | $1,029 |
| Duloxetine Hcl | 47 | $950 |
| Escitalopram Oxalate | 31 | $700 |
| Buspirone Hcl | 35 | $555 |
| Lamotrigine | 15 | $465 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $417 |
| Gabapentin | 23 | $247 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Houston
- Sonam BhaktaHouston$7K
- Carlin BarnesHouston$7K
- Kay LewisHouston$6K
- Ann Menendez-CaldwellHouston$6K
- Sriramamurthy RavipatiHouston$4K
- Cesar Soutullo EsperonHouston$3K
- Peter WuHouston$3K
- Monica GroverHouston$3K
- Charles MorelandHouston$3K
- Zargham AbbasHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.